AlivaMab Biologics’ Post

Catailyst Regulatory Event Snippets: Drug Approval in a Country Approval in China Shanghai Kechow Pharma, Inc. China National Medical Products Administration Approval of Tunlametinib (HL-085), the first approved targeted therapy NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1 #melanoma a potential best-in-class MEK inhibitor based on positive data from the pivotal Phase 2 study #Tunlametinib is a small molecule inhibitor of Mitogen-activated protein kinase kinase (MEK) 

Have you seen the agenda for the Hit ID Summit? See the full event guide via the website here: https://ter.li/ohvqeg Here's a peak at the highlights: 💡 - Tailoring the available, different, screening approaches and match them to your specific targets 💡 - Taking cross learnings from peers and case study presentations to inform hit strategy 💡 - Leveraging DEL, HTS, AI, FBDD, to give a more holistic and detailed picture of how to optimise hit screening With Expert Speakers: Andrew Zhang, Director, Chemical Biology, AstraZeneca Bakhos Tannous, Head, NeuroOncology Discovery, AstraZeneca Christopher Barbieri, Associate Director, Molecular Pharmacology & Screening Technologies, Bristol Myers Squibb Brian Dill, Director, Proteomics, BPGbio, Inc. Yifan Song, Chief Scientific Officer, Cyrus Biotechnology Karenbir Pahil, Investigatior, GSK Spurti Akki, PhD, Senior Scientist, insitro Pat Brady, Senior Director, Computational Chemistry, Kymera Therapeutics Oscar Huang, Associate Director, Biophysics, Lyterian Therapeutics Fabien Vincent, Research Fellow, Pfizer Tim Foley, Lab Head, DNA-Encoded Library, Selection & Pharmacology, Pfizer Woody Sherman, Chief Innovation Officer, Psivant Therapeutics Scott Barraza, Group Leader, Early Discovery Therapeutics, PTC Therapeutics, Inc. Shruthi Bharadwaj, Ph.D, Global Lead, Digital & Analytics, Sanofi Brent Martin, Vice President, Chemical Biology, Scorpion Therapeutics Taosheng Chen, Head of High Throughput Biology, St Jude Children's Hospital Nii Ayi Hesse, Senior Research Scientist, The Francis Crick Institute Rachael Jetson, Senior Director, Lead Discovery, Valo Health Steven Fesik, Professor, Biochemistry, Pharmacology, & Chemistry, Vanderbilt University #hitidentification #hitid #hitscreening #hitfinding #hittolead #drugdiscovery #discovery #undruggable #drugdevelopment #HTS #DEL #dnaencodedlibraries #AI #chemicallibraries

Iktos appoints new Scientific Advisory Board with

Iktos appoints new Scientific Advisory Board with

Iktos appoints new Scientific Advisory Board with

MUST WATCH New routes towards Precision Medicine: Strategic collaboration between CytoReason and the Crohn's & Colitis Foundation From multiomics data sourcing to AI-guided drug discovery CytoReason and the Crohn's & Colitis Foundation recently signed a strategic collaboration to advance IBD research and clinical development. As part of this collaboration, the Foundation's IBD Plexus® real-world data platform will inform CytoReason’s pre-computed disease models. Join Prof. Yehuda Chowers, CytoReason’s Chief Medical Officer, and Dr. Alan Moss, the Foundation's Chief Scientific Officer, as they explore the significance of this collaboration for pharma and biotech companies, and the potential to generate new insights into disease subtypes, treatment pathways, and targeted therapies. #PrecisionMedicine #IBD #Colitis #Inflammation #Autoimmunity #Autoinflammation #Genomics #Genetics #Multiomics #ArtificialIntelligence #Cellbiology #SystemsBiology #Innovation #DrugDiscovery #DrugDevelopment #Biotech #Pharma #Diagnostics #Medicine #Innovation #Biomedicine #ClinicalSciences #ClinicalResearch https://lnkd.in/dzUkW7TE Shai Shen-Orr David H. Zeev Ben-Shachar CytoReason Yehuda Chowers

🎙 This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year.

Catailyst Clinical Event Snippet: First Patient Enrolled/Dosed, Phase 2B MindBio Therapeutics Major Depressive Disorder Phase 2B Take-Home Microdosing (MB22001) Clinical Trial Follows successful Phase 2A trial where 53% of depressed patients were in complete remission from their depression at week 8 marked by a mean 14.1 point drop in MADRS score (Montgomery-Asberg Depression Rating Scale), a 60% mean drop in depressive symptoms. #cns #biotech #depression #biopharma https://lnkd.in/eMddutyN

Oncimmune CEO Martin Gouldstone joins Proactive's Stephen Gunnion with highlights of the company's 2023 performance, which included its strategic decision to focus on its ImmunoINSIGHTS platform. A significant development was the sale of its early lung cancer detection business to US biotech company Freenome, generating substantial funds. This capital was utilised partly to reduce existing company debt and, importantly, established a five-year master service agreement (MSA) with Freenome, guaranteeing Oncimmune a minimum of £1.3 million in service revenues on a use-it-or-lose-it basis, with a two-year break clause. This deal not only provided immediate financial benefit but also assured a steady revenue stream for at least two years. Watch at #Proactive #ProactiveInvestors #Oncimmune #lungcancer #immunotherapy http://ow.ly/2UNP105kM6t

The article reached 3,000 reads Achieved on March 25, 2024 Title: Stimuli-Responsive Polymers for Transdermal, Transmucosal and Ocular Drug Delivery since it was published December 2021 Pharmaceutics 13(12):2050 DOI: 10.3390/pharmaceutics13122050 Despite their conventional and widespread use, oral and intravenous routes of drug administration face several limitations. In particular, orally administered drugs undergo enzymatic degradation in the gastrointestinal tract and first-pass metabolism in the liver, which tend to decrease their bioavailability. Intravenous infusions of medications are invasive, painful and stressful for patients and carry the risk of infections, tissue damage and other adverse reactions. In order to account for these disadvantages, alternative routes of drug delivery, such as transdermal, nasal, oromucosal, ocular and others, have been considered. Moreover, drug formulations have been modified in order to improve their storage stability, solubility, absorption and safety. Recently, stimuli-responsive polymers have been shown to achieve controlled release and enhance the bioavailability of multiple drugs. In this review, we discuss the most up-to-date use of stimuli-responsive materials in order to optimize the delivery of medications that are unstable to pH or undergo primary metabolism via transdermal, nasal, oromucosal and ocular routes. Release kinetics, diffusion parameters and permeation rate of the drug via the mucosa or skin are discussed as well.